These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1126 related articles for article (PubMed ID: 4921328)

  • 1. Suppression of malignancy and differentiation in melanotic melanoma cells.
    Silagi S; Bruce SA
    Proc Natl Acad Sci U S A; 1970 May; 66(1):72-8. PubMed ID: 4921328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of myoblast fusion after one round of DNA synthesis in 5-bromodeoxyuridine.
    Bischoff R; Holtzer H
    J Cell Biol; 1970 Jan; 44(1):134-50. PubMed ID: 4242927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced expression of HLA-DR antigens by the human melanoma cell line CaCL 73-36 upon induction of a less differentiated phenotype with bromodeoxyuridine.
    Kawakubo Y; Liao SK
    Anticancer Res; 1986; 6(5):1197-204. PubMed ID: 3800326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible suppression of malignancy and differentiation of melanoma cells.
    Silagi S
    Am J Pathol; 1977 Dec; 89(3):671-84. PubMed ID: 596422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of 5-bromodeoxyuridine on cyclic AMP levels and cytoskeletal organization in malignant melanoma cells.
    Giotta GJ; Brunson KW; Lotan R
    Cell Biol Int Rep; 1980 Jan; 4(1):105-16. PubMed ID: 6248251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlated suppression by 5-bromodeoxyuridine of tumorigenicity and plasminogen activator in mouse melanoma cells.
    Christman JK; Silagi S; Newcomb EW; Silverstein SC; Acs G
    Proc Natl Acad Sci U S A; 1975 Jan; 72(1):47-50. PubMed ID: 123336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel phenotypes arising from selection of hamster melanoma cells for resistance to BUdR.
    Kaufman ER; Davidson RL
    Exp Cell Res; 1977 Jun; 107(1):15-24. PubMed ID: 558895
    [No Abstract]   [Full Text] [Related]  

  • 8. The effects of 5-bromodeoxyuridine on yolk sac erythropoiesis in the chick embryo.
    Miura Y; Wilt FH
    J Cell Biol; 1971 Mar; 48(3):523-32. PubMed ID: 5101841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects on growth and tumorigenicity of mouse melanoma cells by thymidine and its analogs, 5-ethyl- and 5-bromodeoxyuridine.
    Silagi S; Balint RF; Gauri KK
    Cancer Res; 1977 Sep; 37(9):3367-73. PubMed ID: 884681
    [No Abstract]   [Full Text] [Related]  

  • 10. Tumorigenicity, immunogenicity, and virus production in mouse melanoma cells treated with 5-bromodeoxyuridine.
    Silagi S; Beju D; Wrathall J; Deharven E
    Proc Natl Acad Sci U S A; 1972 Nov; 69(11):3443-7. PubMed ID: 4343973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 5-bromodeoxyuridine (BUdR) on experimental metastasis.
    Zeidman I
    Res Commun Chem Pathol Pharmacol; 1973 May; 5(3):827-35. PubMed ID: 4701271
    [No Abstract]   [Full Text] [Related]  

  • 12. Action of 5-bromodeoxyuridine on the induction of haemoglobin synthesis in mouse leukaemia cells resistant to 5-BUdR.
    Ostertag W; Crozier T; Kluge N; Melderis H; Dube S
    Nat New Biol; 1973 Jun; 243(128):203-5. PubMed ID: 4514957
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of thymidine analogues on murine and human cells.
    Smellie SG; Parsons PG
    Aust J Exp Biol Med Sci; 1979 Dec; 57(6):563-73. PubMed ID: 162036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modification of malignancy by 5-bromodeoxyuridine. Studies of reversibility and immunological effects.
    Silagi S
    In Vitro; 1971; 7(2):105-14. PubMed ID: 5170776
    [No Abstract]   [Full Text] [Related]  

  • 15. Defective transport of thymidine by cultured cells resistant to 5-bromodeoxyuridine.
    Lynch TP; Cass CE; Paterson AR
    J Supramol Struct; 1977; 6(3):363-74. PubMed ID: 145516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of melanoma cell tyrosinase activity and tumorigenicity after incorporation of bromouracil for one or two cell divisions.
    Wrathall JR; Newcomb EW; Balint R; Zeitz L; Silagi S
    J Cell Physiol; 1975 Dec; 86 Suppl 2(3 Pt 2):581-92. PubMed ID: 811676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromodeoxyuridine-induced expression of endothelin A in A375 human melanoma cells.
    Ohtani T; Ninomiya H; Okazawa M; Imamura S; Masaki T
    Biochem Biophys Res Commun; 1997 May; 234(2):526-30. PubMed ID: 9177306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of 5-bromodeoxyuridine on cell division and differentiation of preimplantation mouse embryos.
    Pollard DR; Baran MM; Bachvarova R
    J Embryol Exp Morphol; 1976 Feb; 35(1):169-78. PubMed ID: 1270977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Bromodeoxyuridine-tolerant melanoma cells in vitro and in vivo.
    Pasztor LM; Hu F; McNulty WP
    Yale J Biol Med; 1973 Dec; 46(5):397-410. PubMed ID: 4544338
    [No Abstract]   [Full Text] [Related]  

  • 20. A clonal study of the reversible inhibition of muscle differentiation by the halogenated thymidine analog 5-bromodeoxyuridine.
    Coleman JR; Coleman AW; Hartline EJ
    Dev Biol; 1969 Jun; 19(6):527-48. PubMed ID: 5772670
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 57.